Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ribociclib/ET Improves OS in Premenopausal Women with HR+/HER2- Breast Cancer

Publish date:: June 27, 2019

Key clinical point: A CDK4/6 inhibitor and endocrine therapy combination improved overall survival (OS) rates vs. endocrine therapy alone.

Major finding: In a landmark analysis at 42 months the OS with ribociclib plus endocrine therapy was 70% vs. 46% for placebo plus ET.

Study details: Randomized phase 3 trial with 672 premenopausal women with hormone receptor-positive, HER2-negative breast cancer.

Disclosures: The MONALEESA-7 trial is supported by Novartis. Dr. Hurvitz reported travel and accommodation expenses from Novartis. Dr. Burstein reported no relevant disclosures.

Citation:

Hurvitz SA et al. ASCO 2019. Abstract LBA1008.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,